Methylphenidate Hydrochloride Tablet, Extended Release
Product Images NDC 0406-0127

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 0406-0127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Specgx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Methylphenidate Hydrochloride Er Tablets 1)

Chemical structure of Methylphenidate Hydrochloride (C14H19NO2 · HCl) with a molecular weight of 269.77, showing its molecular framework with functional groups.*

FDA Label Image

Figure 1 (Methylphenidate Hydrochloride Er Tablets 2)

A pharmacokinetic line graph comparing mean plasma methylphenidate concentration (ng/mL) over time (hours) for two dosing regimens: Methylphenidate Hydrochloride Extended-Release 18 mg once daily and Methylphenidate 5 mg taken three times daily. Concentration peaks occur within the first 8 hours before gradually declining to near zero by 28-32 hours.*

FDA Label Image

Figure 2 (Methylphenidate Hydrochloride Er Tablets 3)

A bar chart comparing maximum symptoms on an Inattention/Overactivity Scale between Methylphenidate Hydrochloride Extended-Release Tablets once daily and placebo in three studies. The y-axis ranges from 0 (No Symptoms) to 15 (Maximum Symptoms). Each study shows symptom scores with associated sample sizes noted below the x-axis.*

FDA Label Image

Figure 3 (Methylphenidate Hydrochloride Er Tablets 4)

A line graph comparing the combined attention subscale scores over 12 hours post initial dose between Methylphenidate Hydrochloride Extended-Release tablets once daily and placebo. The y-axis ranges from more attentive to less attentive, and the x-axis shows hours post dose. Data points include mean and standard error for both groups over time.*

FDA Label Image

Principal Display Panel (27 mg Bottle)

Label for Methylphenidate Hydrochloride Extended-Release Tablets USP 27 mg, a prescription oral extended-release tablet. The label indicates the product contains 100 tablets and is distributed by SpecGx LLC. It includes dosage strength, regulatory and storage information, a barcode, and instructions for pharmacists to dispense the Medication Guide separately.*

FDA Label Image

Principal Display Panel (36 mg Bottle)

Label for Methylphenidate Hydrochloride Extended-Release Tablets USP 36 mg, a prescription oral extended-release tablet. The label states the product contains 100 tablets and includes storage and usage instructions. It is labeled for pharmacist dispensing with a medication guide. Manufactured by SpecGx LLC, Webster Groves, MO.*

FDA Label Image

Principal Display Panel (54 mg Bottle)

Label for Methylphenidate Hydrochloride Extended-Release Tablets USP, 54 mg strength. The label indicates the product contains 100 tablets, is prescription only, and includes usage and storage instructions. Labeler is SpecGx LLC, with a reference to Mallinckrodt and barcode and regulatory details visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.